Genelux (GNLX) Net Income towards Common Stockholders (2022 - 2026)

Genelux's (GNLX) quarterly Net Income towards Common Stockholders came in at -$9.3 million in Q1 2026, down 21.02% year-on-year from -$11.8 million in Q1 2025, and up 89.37% quarter-over-quarter from -$87.8 million in Q4 2025.

Genelux (GNLX) Net Income towards Common Stockholders (2022 - 2026) Analysis & Trends

Genelux's Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$9.3 million for Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders fell 21.02% year-over-year to -$9.3 million in Q1 2026; TTM through Mar 2026 was -$116.5 million, a 278.33% decrease from a year earlier, with the FY2025 full-year figure at -$111.0 million, down 21.05% from the prior year.
  • Net Income towards Common Stockholders grew to -$9.3 million in Q1 2026 per GNLX's latest filing, from -$87.8 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $4.9 million in Q3 2022 and bottomed at -$117.2 million in Q2 2023.
  • The 5-year median for Net Income towards Common Stockholders is -$8.1 million (2025), against an average of -$19.6 million.
  • Across the five-year window, Net Income towards Common Stockholders surged 94.26% in 2024 and sank 828.27% in 2025, its largest moves.
  • Year by year, Net Income towards Common Stockholders stood at -$3.5 million in 2022, then sank by 93.62% to -$6.8 million in 2023, then tumbled by 39.78% to -$9.5 million in 2024, then sank by 828.27% to -$87.8 million in 2025, then soared by 89.37% to -$9.3 million in 2026.
  • Per Business Quant, the three latest GNLX Net Income towards Common Stockholders figures stand at -$9.3 million (Q1 2026), -$87.8 million (Q4 2025), and -$11.3 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -625.73
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -14.46 Mn
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -0.68
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 472.00 Mn
9 Revolution Medicines 37.35 Bn 37.35 Bn - -453.82 Mn
10 Genelux 129.36 Mn 129.36 Mn - -9.33 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -9.33 Mn
Dec 31, 2025 -87.81 Mn
Sep 30, 2025 -11.28 Mn
Jun 30, 2025 -8.06 Mn
Mar 31, 2025 -7.71 Mn
Dec 31, 2024 -9.46 Mn
Sep 30, 2024 -6.89 Mn
Jun 30, 2024 -6.73 Mn
Mar 31, 2024 -9.50 Mn
Dec 31, 2023 -6.77 Mn
Sep 30, 2023 -5.35 Mn
Jun 30, 2023 -117.16 Mn
Mar 31, 2023 -9.57 Mn
Dec 31, 2022 -3.50 Mn
Sep 30, 2022 4.91 Mn